BioXcel Therapeutics Inc (NAS:BTAI)
$ 1.97 -0.04 (-1.99%) Market Cap: 73.94 Mil Enterprise Value: 103.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 12, 2022 / 03:00PM GMT
Release Date Price: $10.76 (+11.27%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Welcome to the final day of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. It's my pleasure today to introduce Vimal Mehta, Chief Executive Officer of BioXcel Therapeutics; Matt Wiley, Chief Commercial Officer; and Vince O'Neill, Chief Medical Officer. Vimal, would you like to start off with some opening comments and then we can get into the Q&A?

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Sure. Good morning, everyone, and thank you, Greg, for hosting us here today. BioXcel Therapeutics is a biopharma company using AI platform to develop transformative medicines in neuroscience as well as in immuno-oncology. It has been a very transformative year already, 2022, with the approval of our first drug product. We have 2 lead candidate, BXCL501, which is for acute treatment of agitation resulting from various neuropsychiatric conditions, as well as BXCL701, which is an activator of innate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot